Baxter Falls Despite Q3 Beat as Investors Focus on 2027 Margin Headwinds

Baxter International (BAX) is down 4.2% today. Here is some analysis on what might have caused this price movement.

Analysis: The selloff appears tied less to Baxter’s third-quarter numbers and more to what investors heard about the path ahead. While the company posted revenue growth and raised its 2026 outlook, adjusted earnings were lower than a year ago, and discussion around 2027 margin pressure seems to have overshadowed the quarter’s beat.

Details:

Baxter reported third-quarter sales of about $2.98 billion, up 5% on both a reported and organic basis, with growth across all segments and divisions.

Adjusted diluted EPS was $0.58, which topped consensus expectations, but it was down from $0.69 in the year-ago period, suggesting profitability is still under pressure.

The company raised its full-year 2026 outlook, including adjusted EPS guidance to $2.05 to $2.15 and reported sales growth guidance to 4% to 5%.

This could be because investors focused on management’s comments about 2027 headwinds, including inflation, possible tariff costs, the wind-down of certain Vantive transition support work, and the cephalosporin production exit.

Sources:

Baxter, SEC, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

EARLY ACCESS

Receive BAX Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$BAX Hedge Fund Activity

We have seen 336 institutional investors add shares of $BAX stock to their portfolio, and 284 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC added 7,649,027 shares (+16.5%) to their portfolio in Q2 2026, for an estimated $163,077,255
LAZARD ASSET MANAGEMENT LLC removed 6,188,011 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $131,928,394
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 5,996,711 shares (+inf%) to their portfolio in Q2 2026, for an estimated $127,849,878
UBS GROUP AG added 5,209,812 shares (+120.6%) to their portfolio in Q2 2026, for an estimated $111,073,191
ARTISAN PARTNERS LIMITED PARTNERSHIP removed 3,838,097 shares (-78.9%) from their portfolio in Q2 2026, for an estimated $81,828,228
GOLDMAN SACHS GROUP INC added 3,280,907 shares (+84.8%) to their portfolio in Q2 2026, for an estimated $69,948,937
HOLOCENE ADVISORS, LP added 2,666,396 shares (+inf%) to their portfolio in Q2 2026, for an estimated $56,847,562

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$BAX Price Targets

Multiple analysts have issued price targets for $BAX recently. We have seen 3 analysts offer price targets for $BAX in the last 6 months, with a median target of $24.0.

Here are some recent targets:

Vijay Kumar from Evercore ISI Group set a target price of $24.0 on 07/06/2026
Joanne Wuensch from Citigroup set a target price of $17.0 on 05/28/2026
Matt Miksic from Barclays set a target price of $27.0 on 05/04/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.